Mycobacterium bovis bcg–associated osteomyelitis/osteitis, Taiwan
Journal
Emerging Infectious Diseases
Journal Volume
21
Journal Issue
3
Pages
539-540
Date Issued
2015
Author(s)
Chiu N.-C.
Lin M.-C.
Lin W.-L.
Wang S.-Y.
Chi H.
Tang R.-B.
Huang Y.-C.
Liu C.-C.
Huang F.-Y.
Lin T.-Y.
Abstract
To the Editor: Thirty-eight patients with Mycobacterium bovis BCG–associated osteomyelitis/osteitis, including 8 who were previously reported (1), were identified during Taiwan’s vaccine injury compensation program during 1989–2012; a total of 30 (79%) patients applied for compensation during 2009–2012 (Figure). In Taiwan, a laboratory program to differentiate BCG from other species of the M. tuberculosis complex, using a kit for the Tokyo-172 vaccine strain spoligotyping, was established in 2004 (1). Since 2008, the isolated extrapulmonary tuberculosis strains and pathologic specimens collected from children <5 years of age have been sent to the national reference mycobacterial laboratory for BCG detection (2). The detected incidence of BCG osteitis/osteomyelitis increased from 3.68 cases per million vaccinations during 2002–2006 to 30.1 per million during 2008–2012.
SDGs
Other Subjects
BCG vaccine; ethambutol; isoniazid; pyrazinamide; rifampicin; BCG vaccine; BCG vaccination; bone erosion; child; clinical article; extrapulmonary tuberculosis; fine needle aspiration biopsy; human; human tissue; immune deficiency; incidence; infant; kyphosis; Letter; Mycobacterium bovis BCG; newborn; Taiwan; tuberculin test; tuberculous osteomyelitis; microbiology; osteomyelitis; preschool child; tuberculosis; BCG Vaccine; Child, Preschool; Humans; Incidence; Infant; Infant, Newborn; Osteomyelitis; Taiwan; Tuberculosis
Publisher
Centers for Disease Control and Prevention (CDC)
Type
letter